Catch your breath: The protective role of the angiotensin AT2 receptor for the treatment of idiopathic pulmonary fibrosis
Open Access
- 29 September 2023
- journal article
- review article
- Published by Elsevier in Biochemical Pharmacology
- Vol. 217, 115839
Abstract
No abstract availableKeywords
This publication has 222 references indexed in Scilit:
- Differential Mechanisms of Ang (1-7)-Mediated Vasodepressor Effect in Adult and Aged Candesartan-Treated RatsInternational Journal of Hypertension, 2011
- Multiple stromal populations contribute to pulmonary fibrosis without evidence for epithelial to mesenchymal transitionProceedings of the National Academy of Sciences, 2011
- Moderate cardiac‐selective overexpression of angiotensin II type 2 receptor protects cardiac functions from ischaemic injuryExperimental Physiology, 2011
- Genetic variability in the IL1RN gene and the balance between interleukin (IL)-1 receptor agonist and IL-1β in idiopathic pulmonary fibrosisClinical and Experimental Immunology, 2011
- An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and ManagementAmerican Journal of Respiratory and Critical Care Medicine, 2011
- Repetitive intratracheal bleomycin models several features of idiopathic pulmonary fibrosisAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2010
- Targeted Injury of Type II Alveolar Epithelial Cells Induces Pulmonary FibrosisAmerican Journal of Respiratory and Critical Care Medicine, 2010
- Non-Smad pathways in TGF-β signalingCell Research, 2008
- Short telomeres are a risk factor for idiopathic pulmonary fibrosisProceedings of the National Academy of Sciences, 2008
- Alveolar epithelial cell mesenchymal transition develops in vivo during pulmonary fibrosis and is regulated by the extracellular matrixProceedings of the National Academy of Sciences, 2006